Transient downmodulation of CD20 by rituximab.

被引：0
|
作者：
Jilani, I [1 ]
O'Brien, S [1 ]
Manshouri, T [1 ]
Thomas, DA [1 ]
Thomazy, VA [1 ]
Imam, M [1 ]
Naeem, S [1 ]
Verstovsek, S [1 ]
Kantarjian, H [1 ]
Giles, F [1 ]
Keating, M [1 ]
Albitar, M [1 ]
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
BLOOD | 2002年 / 100卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3174
引用
收藏
页码：804A / 804A
页数：1
相关论文
共 50 条
  • [31] Myeloma with t(11;14) and CD20+plasma cells: Response to rituximab.
    Greipp, PT
    Fonseca, R
    Dewald, D
    Rajkumar, SV
    Morice, WG
    Greipp, PR
    BLOOD, 2005, 106 (11) : 378B - 378B
  • [32] Comparative in vitro activity of two anti-CD20 antibodies - Tositumomab and rituximab.
    Cardarelli, PM
    Quinn, M
    Fang, Y
    Colcher, D
    King, D
    Bebbington, C
    Yarranton, G
    BLOOD, 2000, 96 (11) : 235B - 235B
  • [33] Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 antibody Rituximab.
    Giagounidis, AAN
    Anhuf, J
    Schneider, P
    Germing, U
    Soehngen, D
    Quabeck, K
    Aul, C
    BLOOD, 2001, 98 (11) : 523A - 523A
  • [34] Identification of CD20 mutation associated with modification of CD20 expression and poor prognosis after rituximab in non-Hodgkin's lymphoma
    Terui, Y.
    Mishima, Y.
    Yokoyama, M.
    Kodaira, M.
    Takeuchi, K.
    Hatake, K.
    ANNALS OF ONCOLOGY, 2008, 19 : 115 - 115
  • [35] An anti-C3bi mAb enhances complement activation, C3bi deposition, and killing of CD20 positive cells by Rituximab.
    Taylor, RP
    Kennedy, AD
    Solga, MD
    Schuman, TA
    Chi, A
    Lindorfer, MA
    Sutherland, WM
    FASEB JOURNAL, 2002, 16 (04): : A664 - A664
  • [36] Statins impair antitumor effects of rituximab by inducing conformational changes of CD20
    Winiarska, Magdalena
    Bil, Jacek
    Wilczek, Ewa
    Wilczynski, Grzegorz M.
    Lekka, Malgorzata
    Engelberts, Patrick J.
    Mackus, Wendy J. M.
    Gorska, Elzbieta
    Bojarski, Lukasz
    Stoklosa, Tomasz
    Nowis, Dominika
    Kurzaj, Zuzanna
    Makowski, Marcin
    Glodkowska, Eliza
    Issat, Tadeusz
    Mrowka, Piotr
    Lasek, Witold
    Dabrowska-Iwanicka, Anna
    Basak, Grzegorz W.
    Wasik, Maria
    Warzocha, Krzysztof
    Sinski, Maciej
    Gaciong, Zbigniew
    Jakobisiak, Marek
    Parren, Paul W. H. I.
    Golab, Jakub
    PLOS MEDICINE, 2008, 5 (03) : 0502 - 0517
  • [37] Rituximab with peripheral blood stem cell transplantation in CD20 lymphoproliferative disorders
    Mazza, P
    Palazzo, G
    Amurri, B
    Pricolo, G
    Prudenzano, A
    Stani, L
    HAEMATOLOGICA, 2001, 86 (10) : 1104 - 1105
  • [38] Two structurally different peptides mimic a CD20 epitope recognized by rituximab
    Perosa, F.
    Favoino, E.
    Vicenti, C.
    Prete, M.
    Dammacco, F.
    ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 : A50 - A50
  • [39] CD-20 expression in post-transplant lymphoproliferative disorders(PTLD): Treatment with Rituximab.
    Ifthikharuddin, JJ
    Mieles, LA
    Rosenblatt, JD
    Ryan, CK
    Sahasrabudhe, DM
    BLOOD, 1999, 94 (10) : 248B - 248B
  • [40] Design and characterization of CD20 antigen surface for the selection of rituximab peptide mimics
    Ricloux, Oceane
    Jongwohan, Chanantida
    Cossu, Jordan
    Guerente, Liliane
    Boturyn, Didier
    JOURNAL OF PEPTIDE SCIENCE, 2024, 30
12345